Kuo [64] et al. have recently reported that replacing the glutamate moiety of the PSMA-targeting ligand with Asp, Aad (L-2-aminoadipic acid), and Api (2-aminopimelic acid) led to improvements in tumor-to-kidney and tumor-to-salivary gland ratios in vivo. The gene discussed is FOLH1; the disease is neoplasm.